Alcon/$ALC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Geneva, Switzerland
Employees
25,000
ISIN
CH0432492467
Website
Alcon Metrics
BasicAdvanced
$42B
37.68
$2.25
0.70
$0.18
0.21%
Price and volume
Market cap
$42B
Beta
0.7
52-week high
$99.64
52-week low
$80.48
Average daily volume
1.8M
Dividend rate
$0.18
Financial strength
Current ratio
2.701
Quick ratio
1.455
Long term debt to equity
22.821
Total debt to equity
23.634
Dividend payout ratio (TTM)
11.61%
Interest coverage (TTM)
6.78%
Profitability
EBITDA (TTM)
2,333
Gross margin (TTM)
55.58%
Net profit margin (TTM)
11.28%
Operating margin (TTM)
13.39%
Effective tax rate (TTM)
16.10%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
2.74%
Return on equity (TTM)
5.23%
Valuation
Price to earnings (TTM)
37.675
Price to revenue (TTM)
4.225
Price to book
1.56
Price to tangible book (TTM)
9.97
Price to free cash flow (TTM)
28.863
Free cash flow yield (TTM)
3.46%
Free cash flow per share (TTM)
293.70%
Dividend yield (TTM)
0.21%
Forward dividend yield
0.21%
Growth
Revenue change (TTM)
3.80%
Earnings per share change (TTM)
6.65%
3-year revenue growth (CAGR)
5.10%
3-year earnings per share growth (CAGR)
34.24%
3-year dividend per share growth (CAGR)
12.09%
What the Analysts think about Alcon
Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Bulls say / Bears say
Alcon's strong product pipeline, including upcoming launches in the Surgical and Contact Lens segments, positions the company for significant market share gains. (Investing.com)
The company's robust financial performance, with a 6% increase in annual sales to $9.8 billion and a 16% growth in core diluted EPS to $3.05 in 2024, demonstrates its operational strength. (Seeking Alpha)
Analysts have raised Alcon's stock price targets, reflecting confidence in its growth prospects and market leadership. (Investing.com)
Alcon's high valuation, with a 48x earnings multiple, suggests the stock may be overvalued, potentially limiting future upside. (Seeking Alpha)
The company faces risks from product recalls and supply-chain disruptions, which could negatively impact its operations and financial performance. (Seeking Alpha)
Competitive pressures in the U.S. market, particularly in the Implantables sector, may challenge Alcon's ability to maintain or grow its market share. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 29 May 2025.
Alcon Financial Performance
Revenues and expenses
Alcon Earnings Performance
Company profitability
Alcon News
AllArticlesVideos
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Business Wire·2 hours ago
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
Business Wire·2 weeks ago
US FDA approves Alcon's new dry-eye drug
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alcon stock?
Alcon (ALC) has a market cap of $42B as of June 20, 2025.
What is the P/E ratio for Alcon stock?
The price to earnings (P/E) ratio for Alcon (ALC) stock is 37.68 as of June 20, 2025.
Does Alcon stock pay dividends?
Yes, the Alcon (ALC) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.182 and the yield is 0.21%. Alcon has a payout ratio of 11.61% on a trailing twelve-month basis.
When is the next Alcon dividend payment date?
The next Alcon (ALC) dividend payment date is unconfirmed.
What is the beta indicator for Alcon?
Alcon (ALC) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.